The World Health Organization (WHO) is warning of a "silent pandemic" of antimicrobial resistance. Five million deaths are associated every year due to antimicrobial resistance, according to the release. 2.8 million antimicrobial-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result,
"Antibiotic resistance is one of the major concerns in modern medicine today," Dr. Aaron Glatt, chief of infectious diseases at Mount Sinai South Nassau Hospital on Long Island, New York, explained. "There is a dearth of safe, effective and inexpensive agents to use to treat many of these significant infections. It is critical that new and innovative products be investigated." Glatt added.
Pharmaceutical companies must invest in the research and development phase to find an antimicrobial agent that will combat drug resistant pathogens, experts say. Yet these drugs are as likely to fail during this process as drugs for other diseases that may yield a much better return on the investment, such as cancer and heart drugs.
It's often simply cheaper to bring ‘me-too’ drugs to the market than try and completely redesign a new drug. Look at how many different statin drugs we have that are basically identical. How many SSRI [selective serotonin reuptake inhibitor] depression drugs are available with minimal differences.
You only ever need an antibiotic ideally for a brief period of time, yet a cholesterol drug or an HIV antiviral is forever.